121 related articles for article (PubMed ID: 10674569)
1. Increased perception of dyspnea by inhalation of short acting beta2 agonist in patients with asthma of varying severity.
Jang AS; Choi IS
Ann Allergy Asthma Immunol; 2000 Jan; 84(1):79-83. PubMed ID: 10674569
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-asthma therapy on dyspnea perception in acute asthma patients.
Choi IS; Chung SW; Han ER; Lim JH; Cho JS; Lee YC; Cho S; Jang AS
Respir Med; 2006 May; 100(5):855-61. PubMed ID: 16221548
[TBL] [Abstract][Full Text] [Related]
3. [The effect of time on the perception of dyspnea following inhaled long-acting bronchodilator].
Weiner P; Magadle R; Beckerman M; Berar-Yanay N
Harefuah; 2003 May; 142(5):342-4, 398. PubMed ID: 12803056
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
5. The perception of dyspnoea in patients with asthma, before and following treatment with inhaled glucocorticosteroids.
Weiner P; Berar-Yanay N; Davidovich A; Magadle R; Weiner M
Respir Med; 2000 Feb; 94(2):161-5. PubMed ID: 10714423
[TBL] [Abstract][Full Text] [Related]
6. Dyspnea in acute asthma: relationship with other clinical and physiologic variables.
Janson C; Herala M
Ann Allergy; 1993 May; 70(5):400-4. PubMed ID: 8498732
[TBL] [Abstract][Full Text] [Related]
7. Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics.
Malakauskas K; Sitkauskiene B; Stravinskaite K; Sakalauskas R
J Asthma; 2006 Aug; 43(6):463-7. PubMed ID: 16952866
[TBL] [Abstract][Full Text] [Related]
8. [The relation between the perception of dyspnea and beta 2-agonists consumption in patients with mild-moderate asthma].
Weiner P; Magadle R; Berar-Yanay N; Beckerman M
Harefuah; 2002 Oct; 141(10):865-8, 932, 931. PubMed ID: 12420587
[TBL] [Abstract][Full Text] [Related]
9. Disability and breathlessness in asthmatic patients--a scoring method by repetitive inspiratory effort.
Loh LC; Puah SH; Ho CV; Chow CY; Chua CY; Jayaram J; Kavetha C; Wong SJ
J Asthma; 2005 Dec; 42(10):853-8. PubMed ID: 16393724
[TBL] [Abstract][Full Text] [Related]
10. Perception of dyspnea during exacerbation and histamine-related bronchoconstriction in patients with asthma.
Ekici M; Ekici A; Kara T; Keles H; Karlidag A; Altunkaya V; Bulcun E
Ann Allergy Asthma Immunol; 2006 May; 96(5):707-12. PubMed ID: 16729784
[TBL] [Abstract][Full Text] [Related]
11. [Acute effect of inhaled beta(2)-agonists with different type of intrinsic activity on airway resistance in healthy volunteers].
Kishimoto N; Ohnishi H; Fujita J; Kamei T; Tada S; Ueda N
Arerugi; 2004 Apr; 53(4):417-22. PubMed ID: 15187486
[TBL] [Abstract][Full Text] [Related]
12. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
13. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
14. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
Peters S
Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
[TBL] [Abstract][Full Text] [Related]
15. [Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
Miyagawa T
Arerugi; 2008 Nov; 57(11):1134-44. PubMed ID: 19052508
[TBL] [Abstract][Full Text] [Related]
16. Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
van Schayck CP; Bijl-Hofland ID; Cloosterman SG; Folgering HT; van der Elshout FJ; Van Weel C
Eur Respir J; 2002 Feb; 19(2):240-5. PubMed ID: 11871364
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a positive expiratory pressure device in conjunction with beta2-agonist nebulization therapy for bronchial asthma.
Tsai CF; Tsai JJ
J Microbiol Immunol Infect; 2001 Jun; 34(2):92-6. PubMed ID: 11456366
[TBL] [Abstract][Full Text] [Related]
18. [How can we assess the perception of induced dyspnea in chronic obstructive pulmonary disease?].
Martínez Francés ME; Perpiñá Tordera M; Belloch Fuster A; Martínez Moragón EM; de Diego Damiá A
Arch Bronconeumol; 2004 Apr; 40(4):149-54. PubMed ID: 15030728
[TBL] [Abstract][Full Text] [Related]
19. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Lima JJ; Thomason DB; Mohamed MH; Eberle LV; Self TH; Johnson JA
Clin Pharmacol Ther; 1999 May; 65(5):519-25. PubMed ID: 10340917
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
